Physician profile
Erin Watson
NPI 1699960716
$1,965.76
in general payments reported to CMS, 2019-2025
29 companies · $604 in 2025
The $604 reported for 2025 was more than what 82% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $153 · 2021: $158 · 2022: $85.67 · 2023: $170 · 2024: $502 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,276.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $561.06 | 2023-2025 | Xeomin |
| Abbvie INC. | $422.55 | 2019-2025 | Botox, Ubrelvy |
| Allergan, INC. | $165.70 | 2019-2021 | |
| Painteq LLC | $70.84 | 2024 | Painteq |
| Medtronic, INC. | $69.99 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Collegium Pharmaceutical, INC. | $62.11 | 2019-2020 | |
| Lundbeck LLC | $49.13 | 2024-2025 | Vyepti |
| Spr Therapeutics, INC | $46.66 | 2024 | Sprint Pns System |
| Radius Health, INC. | $46.24 | 2019 | |
| Relievant Medsystems, INC. | $42.12 | 2022-2023 | Intracept |
| Bioventus LLC | $37.91 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $37.75 | 2019-2021 | |
| Redhill Biopharma INC. | $35.93 | 2021 | |
| Pfizer INC. | $32.10 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $29.72 | 2025 | Horizant |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $29.03 | 2019 | |
| Saluda Medical Americas, INC. | $24.35 | 2025 | Evoke |
| Nalu Medical, INC. | $23.82 | 2024 | Nalu Neurostimulation System |
| Assertio Therapeutics, INC. | $19.02 | 2019 | |
| Pacira Therapeutics, INC. | $18.75 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $18.02 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $17.60 | 2025 | |
| Nevro Corp. | $17.19 | 2024 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.37 | 2019 | |
| Depuy Synthes Sales INC. | $15.79 | 2024 | Orthovisc, Monovisc |
| Daiichi Sankyo INC. | $15.26 | 2019 | |
| Biodelivery Sciences International, INC. | $15.18 | 2019 | |
| Lilly USA, LLC | $13.31 | 2020 | |
| Sentynl Therapeutics, INC. | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.